{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-292551","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.495890+00:00","generated_at":"2026-06-07T15:00:38.449701+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ORIC-533 Phase 1 shows clinical activity in multiple myeloma; company to seek partner, extends cash runway to 2026","bullets":["As of Nov 28, 2023, 23 patients dosed (400-2400 mg QD); 100% triple-class refractory, 91% penta-refractory.","No DLTs, dose reductions, or serious TRAEs; only Grade 1-2 TRAEs observed.","Confirmed minor response in a penta-refractory patient who had progressed on anti-BCMA bispecific.","Dose-dependent immune activation (CD8+ T cells, NK cells) at ≥1200 mg; soluble BCMA reductions at 1600 mg.","Company to complete ORIC-533 dose escalation in Q1 2024 then seek partner; focus on ORIC-114 and ORIC-944."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-292551","json":"https://secwatch.observer/filing/0001193125-23-292551.json","markdown":"https://secwatch.observer/filing/0001193125-23-292551.md","text":"https://secwatch.observer/filing/0001193125-23-292551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312523292551/0001193125-23-292551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312523292551/d629143d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:00:38.449701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}